Acquired amegakaryocytic thrombocytopenia after durvalumab administration

Immune checkpoint inhibitors (ICIs), despite their ability to potentiate antitumor T-cell responses, may cause various immune-related adverse events. Most cases of thrombocytopenia induced by ICIs have revealed a pathophysiologic mechanism of immune thrombocytopenia with increased platelet destructi...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Exp Hematop
Hlavní autoři: Suyama, Takahiro, Hagihara, Masao, Kubota, Naoto, Osamura, Yoshiyuki, Shinka, Yoko, Miyao, Naoki
Médium: Artigo
Jazyk:Inglês
Vydáno: JSLRT 2021
Témata:
Case Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8053569/
https://ncbi.nlm.nih.gov/pubmed/33431742
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3960/jslrt.20047
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky